This article only represents the author's own views.
It calls itself a biopharmaceutical company. But that barely covers up a big touch of vanity that’s just below the surface at Cutia Therapeutics, a maker of hair loss products that hopes to thicken up its prospects with a Hong Kong IPO.
In its preliminary prospectus filed earlier this month, the 3-year-old company calls itself a dermatology-focused maker of drugs for scalp diseases and care, skin diseases and care, localized adipose accumulation management and topical anesthesia. It has pipeline of 11 drugs and drug candidates. Two of those have already launched with third-party marketing partners, while another five clinical and four pre-clinical drugs are under development.
您已阅读12%（735字），剩余88%（5347字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。